Welcome reception

Meeting objectives and introduction
David Maloney & Frederick Locke

Welcome to the solid tumors day
Kedar Kirtane & Allison Betof

 Session 1: CARs targeting cell surface proteins (part I)
Chairs: Saul Priceman & Jennifer Specht

• Targeting DTP cells to advance CAR T-cell therapy for solid tumors – NSCLC as a model: Elliott Brea
• LYL273 for refractory metastatic colorectal cancer: Benjamin Schlecter
• Optimizing GPC3 CAR T cells for relapsed/refractory solid tumors: David Steffin
• Intracerebroventricular dual-targeting CAR T cells for glioblastoma: are we on the right path?: Stephen Bagley
• Update in CAR T-cell therapy for breast cancer: Jennifer Specht

Panel discussion

Break

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Eric Smith & TBC                                                                   

• Training T cells for the harsh new world (of solid tumors): Saul Priceman
• GD2 CAR T cell therapy for H3K27-altered diffuse midline gliomas: Jasia Mahdi
• B7H3 CAR-T cell therapy in recurrent platinum resistant epithelial ovarian cancer: Oliver Dorigo
• Innovative allogeneic HER2‑targeted cell therapies: Overcoming barriers in solid tumors: Roisin O’Cearbhaill
• Clinical experience with A2B694, a logic‑gated CAR T therapy to treat solid tumors expressing mesothelin: Jeffrey Ward

Panel discussion

Session 3: T-cell engagers and TCRs for solid tumors
Chairs: Allison Betof & TBC 

• Mechanisms of T-cell immunogenicity against public neoantigens: Smita Chandran
• Targeting PRAME with TCR-T in advanced melanoma: James Smithy
• Targeting cancer testis antigens for synovial sarcoma and myxoid liposarcoma: Michael Wagner
• Clinical development of T-cell engagers in prostate cancer: Progress, promise, and pitfalls: Kevin Zarrabi

Panel discussion

Lunch

Keynote talk 1
Redefining TIL for the treatment of solid cancer: John Haanen

Session 4: TILs for solid tumors
Chairs: Allison Betof & Benjamin Creelan  

• OBX-115 in advanced melanoma: Rodabe Amaria
• Enrichment strategies for TIL in NSCLC: Benjamin Creelan
• TIL sequence in melanoma: Is earlier the right answer?: Daniel Olson
• What matters in TIL infusion: Product characteristics & outcomes: Lilit Karapetyan

Panel discussion           

Break

Session 5: Novel technologies in solid tumors
Chairs: TBC & TBC

• Rewiring solid tumor immunity by genetically engineering myeloid hematopoiesis: Nathan Welty
• LV-based in vivo self-renewing CAR-NK cell factory: Eric Smith
• Cytokine receptor engineering to supercharge CAR T-cells: Sebastian Kobold
• Armored CARs in solid tumors: Renier Brentjens
• Development of a MUC160-targeted and IL-18 armored CAR T-cell for ovarian cancer: Marco Davila
• Utilizing ex vivo CAR T-cell therapy for gastric/GEJ cancers: Changsong Qi

Panel discussion

Session 6: CARs for autoimmune rheumatic disorders
Chairs: David Porter & Jeremias Motte

• Autologous CD19-CAR T in SLE, SSc and IIM – data from the CASTLE-trial: Melanie Hagen
• CABA-201 in SLE: TBC
• BMS-986353: TBC

Panel discussion

Day 1 conclusions
Kedar Kirtane & Allison Betof

 

Welcome reception

Welcome to Day 2
Claire Roddie & Caron Jacobsen

Keynote talk 2
Targeting non-canonical tumor-specific antigens with engineered T cells: Patrick Hwu  

Session 7: CARs for neurological autoimmune diseases
Chairs: Claire Roddie & TBC

• Rapcabtagene autoleucel: Pere Barba
• CAR T-cell therapy in autoimmune neuromuscular diseases: translational insights from miv-cel (KYV-101) in myasthenia gravis, immune-mediated neuropathies, and stiff-person spectrum disorders: Jeremias Motte
• New frontiers, new challenges: CARs for neurological autoimmune diseases: Matthew Lunning
• DESCARTES-08 in MG: Tuan Vu
• Miv-cel therapy in stiff person syndrome: Results from the primary analysis of the KYSA-8 study: Anastasia Zekeridou

Panel discussion

Break

Session 8: T-cell engagers and CARs in CLL
Chairs: Alexey Danilov & David Maloney

• Liso-cel in CLL/SLL: Tanya Siddiqi
• Novel T-cell engagers for CLL/NHL:AZD5492: Mazyar Shadman
• Mechanisms of resistance to CAR T-cell therapy in CLL: Michael Bishop
• The future of therapeutics in Richter’s transformation: CAR-T vs. bispecifics or small molecules: Alexey Danilov

Panel discussion

Session 9: T-cell engagers and CARs in ALL
Chairs: Noelle Frey & Pere Barba

• New generation of CD19-bispecifics in ALL: Ibrahim Aldoss
• Dual-antigen targeting trial in B-ALL: Nirali Shah
• Obe-cel: Bijal Shah

Panel discussion

Lunch

Session 10: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & TBC

• SENTI-202: Stephen Strickland
• CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in relapsed/refractory AML and MDS: Maher Abdul-Hay
• Augmenting memory-like NK cells to overcome AML: Roman Shapiro
• Advances with CAR T-cell therapy in pediatric AML: Swati Naik
• Novel CAR targets and strategies for the treatment of acute myeloid leukemia (AML): Tim Sauer

Panel discussion

Session 11: T-cell engagers in lymphoma
Chairs: Jason Westin & Loretta Nastoupil

• The emerging role of mosunetuzumab as frontline therapy of follicular lymphoma: Lorenzo Falchi
• Epcoritamab: current data and ongoing trials in lymphoid malignancies: Alexey Danilov
• Bispecific antibodies and chemotherapy in LBCL: Is frontline therapy inevitable?: Jason Westin

Panel discussion

Break

Session 12: CARs in lymphoma
Chairs: Jeremy Abramson & Gloria Inés Iacoboni García-Calvo

• NK cell based cellular therapies for B-cell lymphoma: Paolo Strati
• CD5 CAR for T cell lymphoma: Marco Ruella
• JAK inhibition and CAR T-cell therapy: Michael Jain
• Off-the-shelf, CRISPR-edited anti-CD19 CAR T – vispa-cel: Stephen Schuster

Panel discussion

Session 13: Dual-targeting CARs in lymphoma
Chairs: David Miklos & Marie José Kersten

• CD19/CD20 dual targeting CAR T in 2L+ DLBCL: Key data from Prizlo-cel (formerly JNJ-4496): Krish Patel
• Dual-antigen CAR T-cells with bicistronic design and rapid manufacturing with KITE 363/KITE 753 for lymphoma: Saurabh Dahiya
• Clinical results with Zamto-Cel, a dual CD20/CD19 CAR-T, in second- and third-line DLBCL: Nirav Shah
• Ronde-cel, a CD62L enriched CD19/CD20 CAR T-cell candidate, achieves robust expansion, high rates of durable complete response and retains a memory phenotype post-Infusion in patients with LBCL: Akil Merchant
• High CR rates with durable responses in high-risk MCL with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time (ATALANTA-1 MCL cohort): Marie José Kersten

Panel discussion

Day 2 conclusions
Caron Jacobsen

 

Faculty dinner

Welcome to Day 3
Frederick Locke

Keynote talk 3
The lymphoma microenvironment and resistance to CAR T-cell therapy: Michael Green

Session 14: Navigating the broader challenges in CAR T-cell therapy
Chairs: Sarah Nikiforow, Frederick Locke & Loretta Nastoupil

• Non-relapse mortality and long-term risks of CAR T-cell therapy: Kai Rajeski
• Relative cost vs BsABs: Krish Patel
• Regulatory landscape: TBC
• Climbing the CAR T mountain in the community: Tara Graff

Panel discussion

Session 15: in vivo CARs in lymphoma and myeloma
Chairs: Saar Gill & TBC

• in vivo CAR T for hematologic malignancies: Saar Gill
• UB-VV111 for CD19+ B-cell malignancies: Michael Bishop
• ESO‑T01 for R/R multiple myeloma: TBC
• Engineering lentiviral vectors for efficient in vivo CAR-T generation: Kah Whye Peng
• MMyCAR: TBC

Panel discussion

Break – working lunch

Session 16: T-cell engagers for multiple myeloma
Chairs: Sham Mailankody & Yi Lin

• Myeloma intrinsic mechanisms of resistance to T-cell redirected therapies: Francesco Maura
• Immune mechanisms of resistance to T-cell redirected therapies: Holly Lee
• MajesTEC-3 and other teclistamab combinations in earlier liness: Rakesh Popat
• Teclistamab/talquestamab combo and other talquestamab data: TBC
• Linvoseltamab consolidation to ASCT: TBC
• Sequential CAR T cell and bispecific antibody therapy for myeloma: Adam Cohen
• Trispecifics: TBC

Panel discussion

Session 17: CARs for multiple myeloma
Chairs: Adam Cohen & Doris Hansen

• KarMMA-3 -idel-cel: Doris Hansen
• Cilta-cel updates from CARTITUDE 4 and beyond: Rakesh Popat
• Translating anito-cel into the clinic: Emerging data and future directions: Ciara Freeman
• CAR T-cell therapy as first line in newly diagnosed multiple myeloma patients: Juan Du
• CB-011 AlloCART in MM: Adriana Rossi
• GPRC5D-targeting: Sham Mailankody

Panel discussion

Meeting conclusions
Frederick Locke & David Maloney

Meeting close